Literature DB >> 30108795

Quantitative measurement of intracellular HDAC1/2 drug occupancy using a trans-cyclooctene largazole thiol probe.

Hua Xu1, Lee R Roberts1, Song Chou2, Betsy Pierce3, Arjun Narayanan1, Lyn H Jones1.   

Abstract

Histone deacetylases (HDACs) regulate diverse cellular processes, and are promising targets for a number of diseases. Here we describe the design and utilization of a largazole-based chemical probe to quantitatively measure the intracellular occupancy of HDAC1 and HDAC2 by dacinostat. Surprisingly, the probe was unable to enrich HDAC3 despite its nanomolar potency in a biochemical assay, further proving the necessity of cell-based target occupancy assays to understand compound potency in physiologically-relevant settings. This occupancy assay has the potential to aid the development of novel HDAC1/2 inhibitors in drug discovery.

Entities:  

Year:  2017        PMID: 30108795      PMCID: PMC6072125          DOI: 10.1039/c6md00633g

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  30 in total

1.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Authors:  Paul Morgan; Piet H Van Der Graaf; John Arrowsmith; Doug E Feltner; Kira S Drummond; Craig D Wegner; Steve D A Street
Journal:  Drug Discov Today       Date:  2011-12-29       Impact factor: 7.851

2.  Bioorthogonal imaging of aurora kinase A in live cells.

Authors:  Katherine S Yang; Ghyslain Budin; Thomas Reiner; Claudio Vinegoni; Ralph Weissleder
Journal:  Angew Chem Int Ed Engl       Date:  2012-05-29       Impact factor: 15.336

Review 3.  Cell permeable affinity- and activity-based probes.

Authors:  Lyn H Jones
Journal:  Future Med Chem       Date:  2015-10-29       Impact factor: 3.808

Review 4.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 5.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

6.  Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.

Authors:  James E Bradner; Raymond Mak; Shyam K Tanguturi; Ralph Mazitschek; Stephen J Haggarty; Kenneth Ross; Cindy Y Chang; Jocelyn Bosco; Nathan West; Elizabeth Morse; Katherine Lin; John Paul Shen; Nicholas P Kwiatkowski; Nele Gheldof; Job Dekker; Daniel J DeAngelo; Steven A Carr; Stuart L Schreiber; Todd R Golub; Benjamin L Ebert
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

7.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Authors:  Marcus Bantscheff; Carsten Hopf; Mikhail M Savitski; Antje Dittmann; Paola Grandi; Anne-Marie Michon; Judith Schlegl; Yann Abraham; Isabelle Becher; Giovanna Bergamini; Markus Boesche; Manja Delling; Birgit Dümpelfeld; Dirk Eberhard; Carola Huthmacher; Toby Mathieson; Daniel Poeckel; Valérie Reader; Katja Strunk; Gavain Sweetman; Ulrich Kruse; Gitte Neubauer; Nigel G Ramsden; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2011-01-23       Impact factor: 54.908

8.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.

Authors:  Yongcheng Ying; Kanchan Taori; Hyoungsu Kim; Jiyong Hong; Hendrik Luesch
Journal:  J Am Chem Soc       Date:  2008-05-29       Impact factor: 15.419

Review 9.  Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation.

Authors:  Niek Gj Leus; Martijn Rh Zwinderman; Frank J Dekker
Journal:  Curr Opin Chem Biol       Date:  2016-06-29       Impact factor: 8.822

10.  Bioorthogonal tetrazine-mediated transfer reactions facilitate reaction turnover in nucleic acid-templated detection of microRNA.

Authors:  Haoxing Wu; Brandon T Cisneros; Christian M Cole; Neal K Devaraj
Journal:  J Am Chem Soc       Date:  2014-12-19       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.